All enrolled sufferers who gained at least one dose of zosuquidar or placebo for the duration of induction have been monitored for that incidence of adverse functions (439 individuals, 219 on zosuquidar and 210 on placebo). The commonest adverse events were being connected to the period of extended and considerable https://richardi554ufp7.wiki-racconti.com/user